Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > The Numbers

<< Previous

Bullboard Posts

Next >>

Comment by Mbxwatcheron Apr 23, 2021 3:35pm

185 Views

Post# 33056865

RE:The Numbers

Very happy that we have some real traction on VTM.

Taking Q1 numbers is this a stretch?
Antigens + 10% to 2,250
VTM 100kX 4.5 ea = 450K
Qaps + 25 % to = 1.203
Royalties = 60

Total = 3.9 to 4.0 m

An overall increase of 25% with bigger numbers coming in each category for Q3.

I think this is reasonable, He said yesterday that they sold some more VTM in Q2 than just the initial 50K so I am estimating another 50k @ 4.5 per vial.

Its all speculative but does this move the needle on share price?

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023